ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 135 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q3 2018. The put-call ratio across all filers is 0.58 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $746,927 | +9.7% | 28,739 | +20.7% | 0.00% | 0.0% |
Q1 2024 | $681,023 | -2.0% | 23,812 | +4.9% | 0.00% | -33.3% |
Q4 2023 | $694,589 | +13.7% | 22,699 | -0.2% | 0.00% | 0.0% |
Q3 2023 | $611,078 | -10.4% | 22,742 | +19.0% | 0.00% | 0.0% |
Q2 2023 | $681,748 | +51.3% | 19,118 | +7.8% | 0.00% | +50.0% |
Q1 2023 | $450,571 | -24.9% | 17,739 | +19.9% | 0.00% | -33.3% |
Q4 2022 | $600,329 | +37.4% | 14,801 | +12.0% | 0.00% | 0.0% |
Q3 2022 | $437,000 | -6.0% | 13,219 | 0.0% | 0.00% | 0.0% |
Q2 2022 | $465,000 | -23.8% | 13,219 | -0.3% | 0.00% | 0.0% |
Q1 2022 | $610,000 | -37.4% | 13,258 | -9.7% | 0.00% | -40.0% |
Q4 2021 | $974,000 | +42.6% | 14,690 | +34.2% | 0.01% | +25.0% |
Q3 2021 | $683,000 | -24.8% | 10,947 | -0.1% | 0.00% | -20.0% |
Q2 2021 | $908,000 | +18.2% | 10,958 | -5.4% | 0.01% | 0.0% |
Q1 2021 | $768,000 | -16.0% | 11,582 | -2.8% | 0.01% | -16.7% |
Q4 2020 | $914,000 | +92.4% | 11,911 | +8.0% | 0.01% | +100.0% |
Q3 2020 | $475,000 | -0.4% | 11,033 | 0.0% | 0.00% | -25.0% |
Q2 2020 | $477,000 | +102.1% | 11,033 | +34.3% | 0.00% | +100.0% |
Q1 2020 | $236,000 | -34.8% | 8,218 | +44.2% | 0.00% | -33.3% |
Q4 2019 | $362,000 | +124.8% | 5,701 | 0.0% | 0.00% | +200.0% |
Q3 2019 | $161,000 | +17.5% | 5,701 | +10.3% | 0.00% | 0.0% |
Q2 2019 | $137,000 | +44.2% | 5,170 | 0.0% | 0.00% | 0.0% |
Q1 2019 | $95,000 | +3.3% | 5,170 | -30.0% | 0.00% | 0.0% |
Q4 2018 | $92,000 | -35.2% | 7,385 | 0.0% | 0.00% | 0.0% |
Q3 2018 | $142,000 | +42.0% | 7,385 | 0.0% | 0.00% | 0.0% |
Q2 2018 | $100,000 | +4900.0% | 7,385 | +450.3% | 0.00% | – |
Q1 2017 | $2,000 | 0.0% | 1,342 | 0.0% | 0.00% | – |
Q4 2016 | $2,000 | -80.0% | 1,342 | 0.0% | 0.00% | – |
Q3 2016 | $10,000 | +42.9% | 1,342 | 0.0% | 0.00% | – |
Q2 2016 | $7,000 | – | 1,342 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $93,815,000 | 51.06% |
Aquilo Capital Management, LLC | 436,514 | $12,559,000 | 4.90% |
Vivo Capital, LLC | 768,674 | $22,115,000 | 2.00% |
ACUTA CAPITAL PARTNERS, LLC | 109,700 | $3,156,000 | 1.53% |
Prosight Management, LP | 104,737 | $3,013,000 | 1.41% |
Capital Impact Advisors, LLC | 84,537 | $2,432,000 | 1.02% |
Artal Group S.A. | 600,000 | $17,262,000 | 0.73% |
HUSSMAN STRATEGIC ADVISORS, INC. | 62,000 | $1,784,000 | 0.48% |
Quantitative Investment Management, LLC | 150,401 | $4,327,000 | 0.47% |
OAK RIDGE INVESTMENTS LLC | 131,502 | $3,784,000 | 0.39% |